Inhibikase Therapeutics, Inc.
General ticker "IKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $181.8M (TTM average)
Inhibikase Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -10.7%.
Estimated limits based on current volatility of 3.6%: low 1.43$, high 1.54$
Factors to consider:
- Total employees count: 14 as of 2023
- Top business risk factors: Going concern, Capital raising, Economic downturns and volatility, Pandemic risks, Litigation risks
- Current price 55.3% above estimated high
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.34$, 1.17$]
- 2024-12-30 to 2025-12-30 estimated range: [0.29$, 0.97$]
Financial Metrics affecting the IKT estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -265.62 <= 0.33
- Positive: Investing cash flow per share per price, % of 171.20 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 75.68 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term IKT quotes
Long-term IKT plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $3.10MM | $0.12MM | $0.26MM |
| Operating Expenses | $17.87MM | $18.25MM | $20.35MM |
| Operating Income | $-14.77MM | $-18.13MM | $-20.09MM |
| Non-Operating Income | $-0.02MM | $0.18MM | $0.96MM |
| R&D Expense | $11.36MM | $12.03MM | $13.62MM |
| Income(Loss) | $-14.79MM | $-17.95MM | $-19.13MM |
| Profit(Loss)* | $-14.79MM | $-17.95MM | $-19.03MM |
| Stockholders Equity | $38.42MM | $21.04MM | $10.98MM |
| Inventory | $0.11MM | $0.00MM | $0.00MM |
| Assets | $42.47MM | $24.94MM | $14.51MM |
| Operating Cash Flow | $-14.30MM | $-17.35MM | $-18.09MM |
| Capital expenditure | $0.00MM | $0.24MM | $0.01MM |
| Investing Cash Flow | $0.00MM | $-16.01MM | $11.66MM |
| Financing Cash Flow | $41.09MM | $-0.20MM | $8.41MM |
| Earnings Per Share** | $-4.87 | $-4.27 | $-3.57 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.